IQVIA Holdings Inc. reported third-quarter 2026 revenue of $4,428 million, an 8.0% increase year-over-year, with adjusted diluted earnings per share of $3.34, up 11.3%. The company raised its full-year 2026 guidance for adjusted EBITDA to a range of $4,025 million–$4,055 million and adjusted diluted EPS to $12.90–$13.00. R&D Solutions net new bookings reached $3.2 billion, up 15% year-over-year. IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries.
